GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » EV-to-EBITDA

Redhill Biopharma (Redhill Biopharma) EV-to-EBITDA : 0.08 (As of Apr. 25, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Redhill Biopharma's enterprise value is $8.99 Mil. Redhill Biopharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $111.71 Mil. Therefore, Redhill Biopharma's EV-to-EBITDA for today is 0.08.

The historical rank and industry rank for Redhill Biopharma's EV-to-EBITDA or its related term are showing as below:

RDHL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.76   Med: -4.34   Max: 0.08
Current: 0.08

During the past 13 years, the highest EV-to-EBITDA of Redhill Biopharma was 0.08. The lowest was -24.76. And the median was -4.34.

RDHL's EV-to-EBITDA is ranked better than
98.45% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.075 vs RDHL: 0.08

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), Redhill Biopharma's stock price is $0.416243. Redhill Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-3.807. Therefore, Redhill Biopharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Redhill Biopharma EV-to-EBITDA Historical Data

The historical data trend for Redhill Biopharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma EV-to-EBITDA Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.18 -6.68 -2.94 -5.22 0.92

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.38 -5.22 - - -

Competitive Comparison of Redhill Biopharma's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's EV-to-EBITDA falls into.



Redhill Biopharma EV-to-EBITDA Calculation

Redhill Biopharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=8.985/111.714
=0.08

Redhill Biopharma's current Enterprise Value is $8.99 Mil.
Redhill Biopharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $111.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Redhill Biopharma  (NAS:RDHL) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Redhill Biopharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.416243/-3.807
=At Loss

Redhill Biopharma's share price for today is $0.416243.
Redhill Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.807.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Redhill Biopharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.